TY - JOUR

T1 - The value of circulating microRNAs for early diagnosis of B-cell lymphoma

T2 - A case-control study on historical samples

AU - Jørgensen, Steffen

AU - Paulsen, Isabella Worlewenut

AU - Hansen, Jakob Werner

AU - Tholstrup, Dorte

AU - Hother, Christoffer

AU - Sørensen, Erik

AU - Petersen, Mikkel Steen

AU - Nielsen, Kaspar Rene

AU - Rostgaard, Klaus

AU - Larsen, Margit Anita Hørup

AU - Brown, Peter de Nully

AU - Ralfkiær, Elisabeth

AU - Homburg, Keld Mikkelsen

AU - Hjalgrim, Henrik

AU - Erikstrup, Christian

AU - Ullum, Henrik

AU - Troelsen, Jesper

AU - Grønbæk, Kirsten

AU - Pedersen, Ole Birger

PY - 2020

Y1 - 2020

N2 - MicroRNAs are small regulatory RNAs that are deregulated in a wide variety of human cancers, including different types of B-cell lymphoma. Nevertheless, the feasibility of circulating microRNA for early diagnosis of B-cell lymphoma has not been established. To address the possibility of detecting specific circulating microRNAs years before a B-cell lymphoma is diagnosed, we studied the plasma expression of microRNA first in pre-treatment samples from patients with diffuse large B-cell lymphoma and subsequently in repository samples from blood donors who later developed B-cell lymphomas. In addition, we studied the microRNA expression in the diagnostic lymphoma biopsy. The most strongly induced (miR-326) and suppressed (miR-375) plasma microRNA at diagnosis, when compared with healthy blood donors, were also substantially up- or down-regulated in plasma repository samples taken from several months to up to two years before the blood donors were diagnosed with B-cell lymphoma. Importantly, at these time points the donors had no signs of disease and felt healthy enough to donate blood. In conclusion, this first study of plasma microRNA profiles from apparently healthy individuals, taken several years before B-cell lymphoma diagnosis, suggests that plasma microRNA profiles may be predictive of lymphoma development.

AB - MicroRNAs are small regulatory RNAs that are deregulated in a wide variety of human cancers, including different types of B-cell lymphoma. Nevertheless, the feasibility of circulating microRNA for early diagnosis of B-cell lymphoma has not been established. To address the possibility of detecting specific circulating microRNAs years before a B-cell lymphoma is diagnosed, we studied the plasma expression of microRNA first in pre-treatment samples from patients with diffuse large B-cell lymphoma and subsequently in repository samples from blood donors who later developed B-cell lymphomas. In addition, we studied the microRNA expression in the diagnostic lymphoma biopsy. The most strongly induced (miR-326) and suppressed (miR-375) plasma microRNA at diagnosis, when compared with healthy blood donors, were also substantially up- or down-regulated in plasma repository samples taken from several months to up to two years before the blood donors were diagnosed with B-cell lymphoma. Importantly, at these time points the donors had no signs of disease and felt healthy enough to donate blood. In conclusion, this first study of plasma microRNA profiles from apparently healthy individuals, taken several years before B-cell lymphoma diagnosis, suggests that plasma microRNA profiles may be predictive of lymphoma development.

U2 - 10.1038/s41598-020-66062-1

DO - 10.1038/s41598-020-66062-1

M3 - Journal article

C2 - 32541886

AN - SCOPUS:85086433900

VL - 10

JO - Scientific Reports

JF - Scientific Reports

SN - 2045-2322

IS - 1

M1 - 9637

ER -